结果响应率在规划生物类似研究中的作用 使用不同的评估指标
Liyi Cen1, Ramin Arani1, Dejun Tang1
1Sandoz Inc., Princeton, NJ 08540, USA.
Pharmaceuticals (Basel, Switzerland)
|February 26, 2025
概括
评估整体响应率 (ORR) 的生物相似研究可能由于不一致的指标而缺乏力量. 风险差异和风险比率尺度之间的等价边际是不可互换的,这影响了生物类似药物的研究设计和样本大小计算.
科学领域:
- 生物制药产品 生物制药产品
- 临床试验设计 临床试验设计
- 统计分析 统计分析
背景情况:
- 生物相似研究利用整体反应率 (ORR) 来确定临床相似性.
- 样本大小和统计能力取决于等价差额,该等价差额可以通过风险差异或风险比率尺度来定义.
研究的目的:
- 调查不同评估指标和不同响应率对生物类似研究的统计能力的影响.
- 在测试ORR在不同尺度上的等价性时评估结果的一致性.
主要方法:
- 进行了两个数值模拟:一个是风险差异尺度,一个是风险比率尺度.
- 模拟假设生物类药物和参考产品之间没有差异,反应率在0.1到0.9.之间.
- 每个场景都被复制了1万次,以确保可靠的统计分析.
主要成果:
- 测试ORR在风险差异和风险比率等级上的等价性时观察到不一致的结果,即使对于数学上相当的假设.
- 该研究经常发现,在两种尺度上测试等价性的统计能力不足.
- 研究功率表明对结果响应率偏差的敏感性,对两个评估指标的方向影响不同.
结论:
- 生物相似研究设计应避免在假设研究功率不变的情况下,在风险差异和风险比率尺度之间转换等价率.
- 评估总体反应率的战略规划对于在生物类似试验中准确确定样本大小至关重要.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
111
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
111
Bioequivalence: Overview
907
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
907
Dose-Response Relationship: Overview
2.9K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
2.9K
Kaplan-Meier Approach
78
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
78
Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
Analysis of Population Pharmacokinetic Data
214
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
214


